Beyond Symptom Relief: A New Trial Aims to Recalibrate the Cough Reflex

BOSTON, MA – June 30, 2026 – For millions of people worldwide, a persistent cough is not a temporary annoyance but a chronic, debilitating condition that dictates their daily lives. This is the reality of refractory chronic cough (RCC), a relentless state of coughing that persists for months or even years, defying standard treatments. Now, a Boston-based biopharmaceutical company is advancing a novel therapy that aims to do more than just quiet the noise—it seeks to address the biological root of the problem. SC Therapeutics has initiated its REACH2 clinical trial, a pivotal study evaluating a potential first-in-class treatment that could offer not just temporary relief, but a durable reset for the body’s hypersensitive cough reflex.

The Unspoken Burden of a Persistent Cough

Chronic cough, defined as one lasting more than eight weeks, affects an estimated 10% of the global population. A significant portion of these individuals suffer from RCC, where the cough continues despite comprehensive medical investigation and treatment of underlying causes like asthma or acid reflux. The condition disproportionately affects women, who make up roughly two-thirds of cases, with a peak incidence in people aged 40 to 65.

The impact on quality of life is profound, comparable to that of chronic pain or inflammatory bowel disease. Patients report sleep deprivation, social isolation, anxiety, depression, and even physical harm like urinary incontinence. The endless cycle of doctor visits, ineffective medications, and the feeling of being dismissed creates a heavy psychological toll. For this large and underserved patient population, the therapeutic landscape has been bleak, dominated by off-label neuromodulators with limiting side effects and a conspicuous absence of any approved, disease-modifying options.

A Radically Different Approach: Targeting the Root Cause

Instead of continuing down the well-trodden path of symptomatic relief, SC Therapeutics is pioneering a fundamentally different strategy with its lead candidate, SC0032. The company’s approach moves “upstream” from the cough reflex itself to target the underlying mechanical hypersensitivity in the airways. SC0032 is a therapeutic aerosol composed entirely of ions that are naturally present in the human airway lining.

The therapy is designed to deactivate mechano-sensitive ion channels (MSCs), which act as microscopic sensors on airway cells. In chronic cough, these sensors are believed to become overactive, triggering a hair-trigger cough reflex in response to normal stimuli like talking, laughing, or changes in air temperature. By delivering a proprietary formulation of ions, SC0032 aims to relieve the physical compression on these channels, effectively recalibrating them to a normal, less sensitive state.

This mechanism stands in stark contrast to other investigational drugs, such as P2X3 or NK1 receptor antagonists, which work “downstream” by blocking the neural signals that produce a cough. While those drugs can suppress symptoms, their effect is transient. SC Therapeutics hypothesizes that by normalizing MSC activity, SC0032 could be disease-modifying, producing a therapeutic benefit that lasts well beyond the treatment period.

“We are excited by REACH2 and the opportunity it brings to clarify preliminary RCC treatment findings from REACH1, including the rapid reduction of cough and cough bout frequency and the more gradual reduction in cough hypersensitivity we anticipate to occur with the down-regulation of MSCs implicated in hypersensitivity,” said David A. Edwards, scientific founder and CEO of SC Therapeutics. “What we learn from SC0032 will be helpful in understanding treatment possibilities for many respiratory and cardiovascular conditions associated with dehydrated airway mucosa, including all etiologies of chronic cough.”

Designing a Trial for Durability and Precision

To test its ambitious disease-modification hypothesis, SC Therapeutics has engineered the REACH2 trial with a design that emphasizes scientific rigor and precision. The randomized, placebo-controlled study, conducted at premier UK cough centers including Royal Brompton Hospital and King’s College Hospital, will treat patients for three weeks. Critically, it includes a four-week follow-up period after dosing stops. This phase is specifically designed to determine if the therapeutic benefits are sustained, providing the first key evidence of a durable, and therefore potentially disease-modifying, effect.

A major innovation in the trial's methodology is its approach to measuring the primary outcome. A well-documented challenge in cough research is the significant day-to-day variability in cough frequency, which can mask a drug's true efficacy. To overcome this, REACH2 will employ Hyfe's CoughMonitor Suite, a validated, continuous, and objective acoustic monitoring system. The trial’s primary endpoint will compare a full seven continuous days of cough monitoring at baseline with another seven days at the end of the treatment period. This robust, data-rich approach is expected to provide a much clearer and more reliable signal of treatment effect than the shorter, intermittent, or subjective measurements used in many past studies.

A Small Biotech's Big Bet on a New Biology

The initiation of the REACH2 trial represents more than just the next step for a single drug candidate; it’s a significant moment for the field of respiratory medicine. SC Therapeutics, formerly Sensory Cloud Inc., is placing a major bet that modulating the biophysics of airway cells is a more powerful therapeutic strategy than simply blocking nerve signals. If successful, the trial would not only bring a desperately needed solution to millions of RCC sufferers but also validate the company's entire platform targeting mechano-sensitive ion channels.

Success for SC0032 could unlock a new frontier in treating a host of other conditions where aberrant mechanical signaling plays a role, from other respiratory ailments to cardiovascular diseases. For the legions of patients who have been told their cough is something they must simply “learn to live with,” this trial represents a tangible and scientifically-grounded source of hope for a future where they can finally breathe easy.